LEXX$3.91+7.28%
Lexaria Bioscience Corp.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: CAExchange: Nasdaq
Mkt Cap:$8.23M
Float & O/S:
Inst Own:
DilutionScan read 36 of Lexaria Bioscience Corp.'s SEC filings and found 17 warrant series, 1 ATM program, 4 shelf registrations, 2 S-1 registrations and 3 completed offerings on file for LEXX. The latest dilution event on file is a registration statement on Oct 13, 2026. Analysis updated Oct 29, 2026.
Signal8 Summary
LEXX
Losses dwarf revenue, fresh reverse split
- Business
- Weak$11.9M loss vs $706K revenue, $10.5M cash burn
- Stock risk
- High$6M micro-cap, 1-for-15 split, shares +45.3% YoY, 61.5% dilution
Snapshot
Lexaria is a tiny preclinical biotech testing its DehydraTECH drug-delivery platform on GLP-1 compounds. FY2025 revenue grew 52% to $706K, but the company lost $11.9M, roughly 17 times revenue, and burned $10.5M in cash.
What's Happening Right Now
- : On Oct 15, 2026, Lexaria reported preclinical results from animal study GLP-1-A26-1, highlighting a 566% improvement in brain absorption for a DehydraTECH-CBD formulation and filing 3 new patent applications; semaglutide brain-tissue results were non-reportable.
- : On Oct 13, 2026, Lexaria filed a 424B3 prospectus (following an Oct 2 S-3) registering resale of 923,827 shares tied to September 2026 warrant inducement warrants, adding a dilution overhang equal to roughly 30-44% of shares outstanding.
- : Registered additional securities for sale on Form S-1.
- : Registered 924K shares for sale on Form S-3.
- : Raised $5.90M in gross proceeds through an offering, with warrants over 924K shares.
- : On Aug 17, 2026, Nasdaq confirmed Lexaria regained compliance with the minimum bid price rule, cancelling its delisting hearing and removing the delisting overhang.
- : On Aug 13, 2026, Lexaria entered a Material Transfer Agreement with Hong Kong-listed PegBio to test DehydraTECH on a proprietary GLP-1 molecule for diabetes and weight loss.
- : Lexaria's 1-for-15 reverse stock split took effect Aug 3, 2026, cutting shares outstanding from about 24.8 million to 1.65 million to regain Nasdaq's $1.00 minimum bid price compliance.
